Baricitinib shows encouraging phase III results in RA

If baricitinib gains Food and Drug Administration approval for the treatment of RA, Dr. Taylor predicted that as experience is gained, it will be used “relatively early” in the course of treatment, but he acknowledged that cost will enter into the discussion.

Eli Lilly & Co. and Incyte Corporation sponsored the study. All investigators reported ties with Lilly, and some had ties with other companies marketing RA drugs.